Faster Cancer-Fighting cells tested in groundbreaking trial
NCT ID NCT06698744
Summary
This is a first-in-human study to test the safety of a new, experimental CAR-T cell therapy called UF-KURE-BCMA for patients with multiple myeloma that has returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target cancer, but is made using a simpler and faster process than currently approved CAR-T treatments. The main goal is to find a safe dose for future studies, and participants will be closely monitored for side effects for up to 15 years after receiving a single infusion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Cleveland Medical Center Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.